

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number [001-32001](#)

OMB APPROVAL

OMB Number:	3235-0080
Expires:	March 31, 2018
Estimated average burden hours per response:	1.7

Issuer: [Aptose Biosciences Inc.](#)

Exchange: [Nasdaq Stock Market LLC](#)

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address: [5955 Airport Road, Suite 228](#)
[Mississauga ONTARIO, CANADA L4V 1R9](#)

Telephone number: [4,152,184,035](#)

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

[Common Shares](#)

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

☐ 17 CFR 240.12d2-2(a)(1)

☐ 17 CFR 240.12d2-2(a)(2)

☐ 17 CFR 240.12d2-2(a)(3)

☐ 17 CFR 240.12d2-2(a)(4)

☒ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.¹

☐ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements to the Securities Exchange Act of 1934, [Nasdaq Stock Market LLC](#) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

[2025-07-21](#) By

[Aravind Menon](#)
Name

[Hearings Advisor](#)
Title

1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. [See](#) General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Delisting Determination, The Nasdaq Stock Market, LLC, July 11, 2025, Aptose Biosciences, Inc.

The Nasdaq Stock Market LLC (the Exchange) has determined to remove from listing the security of Aptose Biosciences, Inc. effective at the opening of the trading session on July 31, 2025. Based on review of information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Listing Rule 5550(b)(1).

The Company was notified of the Staff determination on October 1, 2024.

On October 8, 2024, the Company exercised its right to appeal the Staff determination to the Listing Qualifications Hearings Panel (Panel) pursuant to Listing Rule 5815.

On November 21, 2024, the hearing was held. On December 17, 2024, the Panel reached a decision and a Decision letter was issued on said date.

On January 14, 2025, Staff issued an Additional Staff Delist Determination Letter notifying the Company that it was in violation of Listing Rule 5550(a)(2).

On March 31, 2025, the Panel reached a decision and decided to suspend the Company from the Exchange since the Company was unable to regain compliance by the milestone set forth in the Decision letter dated December 17, 2024. The Company security was suspended on April 2, 2025. The Staff determination to delist the Company security became final on May 15, 2025.